---
document_datetime: 2025-12-02 06:26:11
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/vocabria.html
document_name: vocabria.html
version: success
processing_time: 0.1165254
conversion_datetime: 2025-12-28 09:55:09.505199
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Vocabria

[RSS](/en/individual-human-medicine.xml/67388)

##### Authorised

This medicine is authorised for use in the European Union

cabotegravir Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Vocabria](#news-on)
- [More information on Vocabria](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Vocabria is used together with another medicine called rilpivirine to treat adults and adolescents aged 12 years and older infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). It is used when the infection is under control with antiretroviral medicines (medicines for HIV). Adolescents must weigh at least 35 kg to take Vocabria.

Vocabria contains the active substance cabotegravir.

Expand section

Collapse section

## How is Vocabria used?

Vocabria is available as tablets to be taken by mouth or as an injection given into a muscle of the hip or buttock. After being injected, the active substance is released slowly over a few weeks into the bloodstream.

Before starting treatment, the doctor ensures that the patient agrees to keep to the schedule of injections because this is important to keep the virus under control and there is a risk that levels of the virus could increase or the virus could become resistant to treatment if doses are missed.

Cabotegravir and rilpivirine tablets are taken daily by mouth for one month, after which Vocabria and rilpivirine injections are given monthly or every 2 months.

If treatment with Vocabria is stopped, another treatment to suppress the virus must be started to minimise the risk that the virus could become resistant to treatment.

Vocabria can only be obtained with a prescription and should be prescribed by a doctor who has experience in the management of HIV infection.

For more information about using Vocabria, including the schedule for the injections, see the package leaflet or contact your doctor or pharmacist.

## How does Vocabria work?

Vocabria is an integrase inhibitor. This is a medicine that blocks an enzyme called integrase that the virus needs to make new copies of itself in the body. By blocking this enzyme, Vocabria, taken together with rilpivirine, reduces the amount of HIV in the blood and keeps it at a low level. Vocabria does not cure HIV infection or AIDS, but it can hold off damage to the immune system and the development of infections and diseases associated with AIDS.

## What benefits of Vocabria have been shown in studies?

Vocabria, taken together with rilpivirine, was as effective as other HIV medicines in maintaining HIV-1 level in the blood (viral load) below a defined level (less than 50 HIV-1 RNA copies/ml) in 3 main studies involving adults with HIV-1 infection. The studies involved patients who had not taken HIV medicines before or who had been taking these medicines for at least 6 months.

In the first two studies, patients were treated with Vocabria and rilpivirine or with combinations of other medicines. After 48 weeks of treatment, the HIV-1 level was above the limit in 1.9% of patients (11 out of 591) taking monthly injections of Vocabria and rilpivirine and in 1.7% of patients (10 out of 591) taking other medicines.

The third study showed that injections of Vocabria and rilpivirine given monthly or every 2 months were similarly effective. After 48 weeks of treatment, the HIV-1 level was above the limit in 1.7% of patients (9 out of 522) given injections every 2 months, compared with 1% of patients (5 out of 523) who had monthly injections.

A further study showed that giving Vocabria to adolescents aged 12 years and older and weighing at least 35 kg resulted in blood levels of the active substance similar to those seen in adults. Therefore, the medicine is expected to have similar effects in adolescents.

## What are the risks associated with Vocabria?

For the full list of side effects and restrictions with Vocabria, see the package leaflet.

The most common side effects with Vocabria and rilpivirine monthly injections (which may affect more than 1 in 10 people) include injection site reactions, headache and fever.

Vocabria must not be used with the following medicines as they may lead to reduced blood levels of the medicine, reducing its effectiveness:

- carbamazepine, oxcarbazepine, phenobarbital and phenytoin (medicines for epilepsy);
- rifampicin and rifapentine (antibiotics).

## Why is Vocabria authorised in the EU?

Injections of Vocabria every month or every 2 months may be more convenient for patients than taking medicines every day. Studies showed that the medicine was as effective at keeping the virus level low as other standard medicines. It is important that patients keep to the schedule of injections to avoid the virus becoming resistant to treatment, and further studies will determine whether this is happening while the medicine is on the market.

## What measures are being taken to ensure the safe and effective use of Vocabria?

The company that markets Vocabria will carry out 2 studies on how the medicine is used and its effectiveness. The outcomes for patients who switch to other treatments after taking Vocabria will also be studied.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vocabria have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Vocabria are continuously monitored. Side effects reported with Vocabria are carefully evaluated and any necessary action taken to protect patients.

## Other information about Vocabria

Vocabria received a marketing authorisation valid throughout the EU on 17 December 2020.

Vocabria : EPAR - Medicine overview

Reference Number: EMA/565621/2020

English (EN) (147.88 KB - PDF)

**First published:** 05/01/2021

**Last updated:** 12/03/2025

[View](/en/documents/overview/vocabria-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-985)

български (BG) (174.74 KB - PDF)

**First published:**

05/01/2021

**Last updated:**

12/03/2025

[View](/bg/documents/overview/vocabria-epar-medicine-overview_bg.pdf)

español (ES) (147.85 KB - PDF)

**First published:**

05/01/2021

**Last updated:**

12/03/2025

[View](/es/documents/overview/vocabria-epar-medicine-overview_es.pdf)

čeština (CS) (172.13 KB - PDF)

**First published:**

05/01/2021

**Last updated:**

12/03/2025

[View](/cs/documents/overview/vocabria-epar-medicine-overview_cs.pdf)

dansk (DA) (147.64 KB - PDF)

**First published:**

05/01/2021

**Last updated:**

12/03/2025

[View](/da/documents/overview/vocabria-epar-medicine-overview_da.pdf)

Deutsch (DE) (151.29 KB - PDF)

**First published:**

05/01/2021

**Last updated:**

12/03/2025

[View](/de/documents/overview/vocabria-epar-medicine-overview_de.pdf)

eesti keel (ET) (145.29 KB - PDF)

**First published:**

05/01/2021

**Last updated:**

12/03/2025

[View](/et/documents/overview/vocabria-epar-medicine-overview_et.pdf)

ελληνικά (EL) (173.6 KB - PDF)

**First published:**

05/01/2021

**Last updated:**

12/03/2025

[View](/el/documents/overview/vocabria-epar-medicine-overview_el.pdf)

français (FR) (148.33 KB - PDF)

**First published:**

05/01/2021

**Last updated:**

12/03/2025

[View](/fr/documents/overview/vocabria-epar-medicine-overview_fr.pdf)

hrvatski (HR) (169.91 KB - PDF)

**First published:**

05/01/2021

**Last updated:**

12/03/2025

[View](/hr/documents/overview/vocabria-epar-medicine-overview_hr.pdf)

italiano (IT) (146.87 KB - PDF)

**First published:**

05/01/2021

**Last updated:**

12/03/2025

[View](/it/documents/overview/vocabria-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (185.89 KB - PDF)

**First published:**

05/01/2021

**Last updated:**

12/03/2025

[View](/lv/documents/overview/vocabria-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (170.19 KB - PDF)

**First published:**

05/01/2021

**Last updated:**

12/03/2025

[View](/lt/documents/overview/vocabria-epar-medicine-overview_lt.pdf)

magyar (HU) (169.58 KB - PDF)

**First published:**

05/01/2021

**Last updated:**

12/03/2025

[View](/hu/documents/overview/vocabria-epar-medicine-overview_hu.pdf)

Malti (MT) (172.65 KB - PDF)

**First published:**

05/01/2021

**Last updated:**

12/03/2025

[View](/mt/documents/overview/vocabria-epar-medicine-overview_mt.pdf)

Nederlands (NL) (148.84 KB - PDF)

**First published:**

05/01/2021

**Last updated:**

12/03/2025

[View](/nl/documents/overview/vocabria-epar-medicine-overview_nl.pdf)

polski (PL) (173.49 KB - PDF)

**First published:**

05/01/2021

**Last updated:**

12/03/2025

[View](/pl/documents/overview/vocabria-epar-medicine-overview_pl.pdf)

português (PT) (148.64 KB - PDF)

**First published:**

05/01/2021

**Last updated:**

12/03/2025

[View](/pt/documents/overview/vocabria-epar-medicine-overview_pt.pdf)

română (RO) (167.88 KB - PDF)

**First published:**

05/01/2021

**Last updated:**

12/03/2025

[View](/ro/documents/overview/vocabria-epar-medicine-overview_ro.pdf)

slovenčina (SK) (170.15 KB - PDF)

**First published:**

05/01/2021

**Last updated:**

12/03/2025

[View](/sk/documents/overview/vocabria-epar-medicine-overview_sk.pdf)

slovenščina (SL) (168.2 KB - PDF)

**First published:**

05/01/2021

**Last updated:**

12/03/2025

[View](/sl/documents/overview/vocabria-epar-medicine-overview_sl.pdf)

Suomi (FI) (145.57 KB - PDF)

**First published:**

05/01/2021

**Last updated:**

12/03/2025

[View](/fi/documents/overview/vocabria-epar-medicine-overview_fi.pdf)

svenska (SV) (146.04 KB - PDF)

**First published:**

05/01/2021

**Last updated:**

12/03/2025

[View](/sv/documents/overview/vocabria-epar-medicine-overview_sv.pdf)

Vocabria : EPAR - Risk management plan

English (EN) (1.45 MB - PDF)

**First published:** 05/01/2021

**Last updated:** 30/10/2025

[View](/en/documents/rmp/vocabria-epar-risk-management-plan_en.pdf)

## Product information

Vocabria : EPAR - Product Information

English (EN) (1.72 MB - PDF)

**First published:** 05/01/2021

**Last updated:** 09/09/2025

[View](/en/documents/product-information/vocabria-epar-product-information_en.pdf)

[Other languages (22)](#file-language-dropdown-505)

español (ES) (1.86 MB - PDF)

**First published:**

05/01/2021

**Last updated:**

09/09/2025

[View](/es/documents/product-information/vocabria-epar-product-information_es.pdf)

dansk (DA) (4.45 MB - PDF)

**First published:**

05/01/2021

**Last updated:**

09/09/2025

[View](/da/documents/product-information/vocabria-epar-product-information_da.pdf)

Deutsch (DE) (5.6 MB - PDF)

**First published:**

05/01/2021

**Last updated:**

09/09/2025

[View](/de/documents/product-information/vocabria-epar-product-information_de.pdf)

eesti keel (ET) (4.28 MB - PDF)

**First published:**

05/01/2021

**Last updated:**

09/09/2025

[View](/et/documents/product-information/vocabria-epar-product-information_et.pdf)

ελληνικά (EL) (4.64 MB - PDF)

**First published:**

05/01/2021

**Last updated:**

09/09/2025

[View](/el/documents/product-information/vocabria-epar-product-information_el.pdf)

français (FR) (5.48 MB - PDF)

**First published:**

05/01/2021

**Last updated:**

09/09/2025

[View](/fr/documents/product-information/vocabria-epar-product-information_fr.pdf)

hrvatski (HR) (4.54 MB - PDF)

**First published:**

05/01/2021

**Last updated:**

09/09/2025

[View](/hr/documents/product-information/vocabria-epar-product-information_hr.pdf)

íslenska (IS) (4.82 MB - PDF)

**First published:**

05/01/2021

**Last updated:**

09/09/2025

[View](/is/documents/product-information/vocabria-epar-product-information_is.pdf)

italiano (IT) (5.14 MB - PDF)

**First published:**

05/01/2021

**Last updated:**

09/09/2025

[View](/it/documents/product-information/vocabria-epar-product-information_it.pdf)

latviešu valoda (LV) (4.21 MB - PDF)

**First published:**

05/01/2021

**Last updated:**

09/09/2025

[View](/lv/documents/product-information/vocabria-epar-product-information_lv.pdf)

lietuvių kalba (LT) (4.59 MB - PDF)

**First published:**

05/01/2021

**Last updated:**

09/09/2025

[View](/lt/documents/product-information/vocabria-epar-product-information_lt.pdf)

magyar (HU) (1.88 MB - PDF)

**First published:**

05/01/2021

**Last updated:**

09/09/2025

[View](/hu/documents/product-information/vocabria-epar-product-information_hu.pdf)

Malti (MT) (5.36 MB - PDF)

**First published:**

05/01/2021

**Last updated:**

09/09/2025

[View](/mt/documents/product-information/vocabria-epar-product-information_mt.pdf)

Nederlands (NL) (4.59 MB - PDF)

**First published:**

05/01/2021

**Last updated:**

09/09/2025

[View](/nl/documents/product-information/vocabria-epar-product-information_nl.pdf)

norsk (NO) (4.62 MB - PDF)

**First published:**

05/01/2021

**Last updated:**

09/09/2025

[View](/no/documents/product-information/vocabria-epar-product-information_no.pdf)

polski (PL) (4.67 MB - PDF)

**First published:**

05/01/2021

**Last updated:**

09/09/2025

[View](/pl/documents/product-information/vocabria-epar-product-information_pl.pdf)

português (PT) (1.76 MB - PDF)

**First published:**

05/01/2021

**Last updated:**

09/09/2025

[View](/pt/documents/product-information/vocabria-epar-product-information_pt.pdf)

română (RO) (4.26 MB - PDF)

**First published:**

05/01/2021

**Last updated:**

09/09/2025

[View](/ro/documents/product-information/vocabria-epar-product-information_ro.pdf)

slovenčina (SK) (5.95 MB - PDF)

**First published:**

05/01/2021

**Last updated:**

09/09/2025

[View](/sk/documents/product-information/vocabria-epar-product-information_sk.pdf)

slovenščina (SL) (5.02 MB - PDF)

**First published:**

05/01/2021

**Last updated:**

09/09/2025

[View](/sl/documents/product-information/vocabria-epar-product-information_sl.pdf)

Suomi (FI) (4.67 MB - PDF)

**First published:**

05/01/2021

**Last updated:**

09/09/2025

[View](/fi/documents/product-information/vocabria-epar-product-information_fi.pdf)

svenska (SV) (4.34 MB - PDF)

**First published:**

05/01/2021

**Last updated:**

09/09/2025

[View](/sv/documents/product-information/vocabria-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0000256925 14/08/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Vocabria : EPAR - All authorised presentations

English (EN) (17.55 KB - PDF)

**First published:** 05/01/2021

[View](/en/documents/all-authorised-presentations/vocabria-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-10)

български (BG) (39.28 KB - PDF)

**First published:**

05/01/2021

[View](/bg/documents/all-authorised-presentations/vocabria-epar-all-authorised-presentations_bg.pdf)

español (ES) (18.92 KB - PDF)

**First published:**

05/01/2021

[View](/es/documents/all-authorised-presentations/vocabria-epar-all-authorised-presentations_es.pdf)

čeština (CS) (37.95 KB - PDF)

**First published:**

05/01/2021

[View](/cs/documents/all-authorised-presentations/vocabria-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (18.49 KB - PDF)

**First published:**

05/01/2021

[View](/da/documents/all-authorised-presentations/vocabria-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (18.27 KB - PDF)

**First published:**

05/01/2021

[View](/de/documents/all-authorised-presentations/vocabria-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (17.08 KB - PDF)

**First published:**

05/01/2021

[View](/et/documents/all-authorised-presentations/vocabria-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (42.4 KB - PDF)

**First published:**

05/01/2021

[View](/el/documents/all-authorised-presentations/vocabria-epar-all-authorised-presentations_el.pdf)

français (FR) (16.53 KB - PDF)

**First published:**

05/01/2021

[View](/fr/documents/all-authorised-presentations/vocabria-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (38.3 KB - PDF)

**First published:**

05/01/2021

[View](/hr/documents/all-authorised-presentations/vocabria-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (16.1 KB - PDF)

**First published:**

05/01/2021

[View](/is/documents/all-authorised-presentations/vocabria-epar-all-authorised-presentations_is.pdf)

italiano (IT) (18.79 KB - PDF)

**First published:**

05/01/2021

[View](/it/documents/all-authorised-presentations/vocabria-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (40.63 KB - PDF)

**First published:**

05/01/2021

[View](/lv/documents/all-authorised-presentations/vocabria-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (41.76 KB - PDF)

**First published:**

05/01/2021

[View](/lt/documents/all-authorised-presentations/vocabria-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (31.75 KB - PDF)

**First published:**

05/01/2021

[View](/hu/documents/all-authorised-presentations/vocabria-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (37.5 KB - PDF)

**First published:**

05/01/2021

[View](/mt/documents/all-authorised-presentations/vocabria-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (18.98 KB - PDF)

**First published:**

05/01/2021

[View](/nl/documents/all-authorised-presentations/vocabria-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (17.89 KB - PDF)

**First published:**

05/01/2021

[View](/no/documents/all-authorised-presentations/vocabria-epar-all-authorised-presentations_no.pdf)

polski (PL) (39.24 KB - PDF)

**First published:**

05/01/2021

[View](/pl/documents/all-authorised-presentations/vocabria-epar-all-authorised-presentations_pl.pdf)

português (PT) (17.6 KB - PDF)

**First published:**

05/01/2021

[View](/pt/documents/all-authorised-presentations/vocabria-epar-all-authorised-presentations_pt.pdf)

română (RO) (37.74 KB - PDF)

**First published:**

05/01/2021

[View](/ro/documents/all-authorised-presentations/vocabria-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (39.1 KB - PDF)

**First published:**

05/01/2021

[View](/sk/documents/all-authorised-presentations/vocabria-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (34.8 KB - PDF)

**First published:**

05/01/2021

[View](/sl/documents/all-authorised-presentations/vocabria-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (19.48 KB - PDF)

**First published:**

05/01/2021

[View](/fi/documents/all-authorised-presentations/vocabria-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (14.09 KB - PDF)

**First published:**

05/01/2021

[View](/sv/documents/all-authorised-presentations/vocabria-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Vocabria Active substance

- cabotegavir sodium
- cabotegravir

International non-proprietary name (INN) or common name cabotegravir Therapeutic area (MeSH) HIV Infections Anatomical therapeutic chemical (ATC) code J05AX

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents (at least 12 years of age and weighing at least 35 kg) who are virologically suppressed (HIV-1 RNA &lt;50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the non-nucleoside reverse transcriptase inhibitor (NNRTI) and integrase inhibitor (INI) class for:

- Oral lead in to assess tolerability of Vocabria and rilpivirine prior to administration of long acting cabotegravir injection plus long acting rilpivirine injection.
- Oral therapy for adults and adolescents who will miss planned dosing with cabotegravir injection plus rilpivirine injection.

Vocabria injection is indicated, in combination with rilpivirine injection, for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adoloscents (at least 12 years of age and weighing at least 35 kg) who are virologically suppressed (HIV-1 RNA &lt;50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the non-nucleoside reverse trascriptase.

## Authorisation details

EMA product number EMEA/H/C/004976

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

ViiV Healthcare B.V.

Van Asch van Wijckstraat 55 H

Opinion adopted 15/10/2020 Marketing authorisation issued 17/12/2020 Revision 17

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Vocabria : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (148.57 KB - PDF)

**First published:** 09/09/2025

**Last updated:** 30/10/2025

[View](/en/documents/procedural-steps-after/vocabria-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Vocabria : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (157.57 KB - PDF)

**First published:** 11/03/2021

**Last updated:** 09/09/2025

[View](/en/documents/procedural-steps-after/vocabria-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Vocabria-H-C-004976-II-0022 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/1951/2025

English (EN) (2.63 MB - PDF)

**First published:** 22/01/2025

[View](/en/documents/variation-report/vocabria-h-c-004976-ii-0022-epar-assessment-report-variation_en.pdf)

Vocabria-H-C-PSUSA-00010900-202403 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/596127/2024

English (EN) (197.25 KB - PDF)

**First published:** 19/12/2024

[View](/en/documents/scientific-conclusion/vocabria-h-c-psusa-00010900-202403-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

CHMP post-authorisation summary of positive opinion for Vocabria (II-22)

Adopted

Reference Number: EMA/559372/2024

English (EN) (160.92 KB - PDF)

**First published:** 13/12/2024

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vocabria-ii-22_en.pdf)

Vocabria-H-C-PSUSA-00010900-202203 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/859633/2022

English (EN) (146.91 KB - PDF)

**First published:** 12/01/2023

[View](/en/documents/scientific-conclusion/vocabria-h-c-psusa-00010900-202203-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Vocabria-H-C-PSUSA-00010900-202109 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/10440/2022

English (EN) (117.91 KB - PDF)

**First published:** 27/01/2022

[View](/en/documents/scientific-conclusion/vocabria-h-c-psusa-00010900-202109-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Vocabria : EPAR - Public assessment report

Adopted

Reference Number: EMA/586324/2020

English (EN) (8.41 MB - PDF)

**First published:** 05/01/2021

[View](/en/documents/assessment-report/vocabria-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Vocabria

Adopted

Reference Number: EMA/CHMP/447977/2020

English (EN) (170.14 KB - PDF)

**First published:** 16/10/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-vocabria_en.pdf)

#### News on Vocabria

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-december-2024) 13/12/2024

[First long-acting injectable antiretroviral therapy for HIV recommended for approval](/en/news/first-long-acting-injectable-antiretroviral-therapy-hiv-recommended-approval) 16/10/2020

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2020) 16/10/2020

#### More information on Vocabria

- [EMEA-001418-PIP01-13-M05 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001418-pip01-13-m05)
- [EMEA-001418-PIP02-15-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001418-pip02-15-m03)
- [Pregnancy and Neonatal Outcomes following Prenatal Exposure to Cabotegravir: Data from The Antiretroviral Pregnancy Registry (APR) (215325) - post-authorisation study](https://catalogues.ema.europa.eu/study/47339)
- [CABFIDENCE: Global Real-World Evidence Cohort Study to evaluate Utilization, Clinical and Patient-Reported Outcomes among CAB+RPV LA users (224047) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000616)
- [Pregnancy and Neonatal Outcomes following Prenatal Exposure to Cabotegravir Long Acting (CAB LA): Data from the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) (215163) - post-authorisation study](https://catalogues.ema.europa.eu/study/47336)
- [Drug Utilization, Adherence, Effectiveness and Resistance: A Prospective Observational Cohort Study in People living with HIV (PLWH) initiating ARV regimen CAB+RPV LA in Collaboration with EuroSIDA (215161) - post-authorisation study](https://catalogues.ema.europa.eu/study/46179)
- [Drug Utilization, Adherence, Effectiveness and Resistance: A Prospective Observational Cohort Study in People living with HIV (PLWH) initiating ARV regimen CAB+RPV LA in Collaboration with EuroSIDA (215161) - post-authorisation study](https://catalogues.ema.europa.eu/study/46179)
- [Drug Utilization, Adherence, Effectiveness and Resistance: A Prospective Observational Cohort Study in People living with HIV (PLWH) initiating ARV regimen CAB+RPV LA in Collaboration with EuroSIDA (215161) - post-authorisation study](https://catalogues.ema.europa.eu/study/46179)
- [Drug Utilization, Adherence, Effectiveness and Resistance: A Prospective Observational Cohort Study in People living with HIV (PLWH) initiating ARV regimen CAB+RPV LA in Collaboration with EuroSIDA (215161) - post-authorisation study](https://catalogues.ema.europa.eu/study/46179)
- [C2C: COMBINE-2 for Cabotegravir+Rilpivirine LA Regimen - A Prospective Cohort Study to Monitor Effectiveness, Adherence and Resistance (215160) - post-authorisation study](https://catalogues.ema.europa.eu/study/49488)
- [C2C: COMBINE-2 for Cabotegravir+Rilpivirine LA Regimen - A Prospective Cohort Study to Monitor Effectiveness, Adherence and Resistance (215160) - post-authorisation study](https://catalogues.ema.europa.eu/study/49488)
- [C2C: COMBINE-2 for Cabotegravir+Rilpivirine LA Regimen - A Prospective Cohort Study to Monitor Effectiveness, Adherence and Resistance (215160) - post-authorisation study](https://catalogues.ema.europa.eu/study/49488)
- [C2C: COMBINE-2 for Cabotegravir+Rilpivirine LA Regimen - A Prospective Cohort Study to Monitor Effectiveness, Adherence and Resistance (215160) - post-authorisation study](https://catalogues.ema.europa.eu/study/49488)

**This page was last updated on** 30/10/2025

## Share this page

[Back to top](#main-content)